AIM: Medication adherence is a determining factor for symptomatic remission and relapse prevention following a first episode of psychosis (FEP). Neurocognitive abilities have received only scant attention so far as a risk factor for poor adherence but significant impairments with memory and/or planning abilities could play a role. We examined early medication adherence following admission to a specialized clinical programme for FEP. METHOD: One hundred sixty FEP participants and 35 healthy controls completed an exhaustive neurocognitive assessment. FEP participants were categorized as a function of their medication adherence at 6 months into poor (n = 34), partial (n = 27) and full (n = 99) adherence, respectively. Domain-specific and global measures of cognitive ability were examined. RESULTS: No measure of neurocognition could significantly discriminate amongst the three medication adherence groups. CONCLUSION: These results suggest no strong associations between neurocognitive abilities and medication adherence in first episode of psychosis.
AIM: Medication adherence is a determining factor for symptomatic remission and relapse prevention following a first episode of psychosis (FEP). Neurocognitive abilities have received only scant attention so far as a risk factor for poor adherence but significant impairments with memory and/or planning abilities could play a role. We examined early medication adherence following admission to a specialized clinical programme for FEP. METHOD: One hundred sixty FEP participants and 35 healthy controls completed an exhaustive neurocognitive assessment. FEP participants were categorized as a function of their medication adherence at 6 months into poor (n = 34), partial (n = 27) and full (n = 99) adherence, respectively. Domain-specific and global measures of cognitive ability were examined. RESULTS: No measure of neurocognition could significantly discriminate amongst the three medication adherence groups. CONCLUSION: These results suggest no strong associations between neurocognitive abilities and medication adherence in first episode of psychosis.
Authors: Richard J Drake; Merete Nordentoft; Gillian Haddock; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Marion Leboyer; Stefan Leucht; Markus Leweke; Phillip McGuire; Andreas Meyer-Lindenberg; Dan Rujescu; Iris E Sommer; René S Kahn; Shon W Lewis Journal: Schizophr Bull Date: 2015-03-05 Impact factor: 9.306
Authors: Emmanuel Stip; Philippe D Vincent; Juliette Sablier; Catherine Guevremont; Simon Zhornitsky; Constantin Tranulis Journal: Front Pharmacol Date: 2013-08-09 Impact factor: 5.810
Authors: Dawn I Velligan; Martha Sajatovic; Ainslie Hatch; Pavel Kramata; John P Docherty Journal: Patient Prefer Adherence Date: 2017-03-03 Impact factor: 2.711
Authors: Sophie-Kathrin Kirchner; Michael Lauseker; Kristina Adorjan; Heike Anderson-Schmidt; Ion-George Anghelescu; Bernhardt T Baune; Monika Budde; Udo Dannlowski; Detlef E Dietrich; Andreas J Fallgatter; Peter Falkai; Christian Figge; Katrin Gade; Urs Heilbronner; Lena Hiendl; Georg Juckel; Janos L Kalman; Farahnaz Klöhn-Saghatolislam; Carsten Konrad; Fabian U Lang; Mojtaba Oraki Kohshour; Sergi Papiol; Daniela Reich-Erkelenz; Jens Reimer; Eva Z Reininghaus; Sabrina K Schaupp; Max Schmauß; Andrea Schmitt; Eva Christina Schulte; Simon Senner; Carsten Spitzer; Thomas Vogl; Jörg Zimmermann; Alkomiet Hasan; Thomas G Schulze; Fanny Senner Journal: Front Psychiatry Date: 2022-01-20 Impact factor: 4.157
Authors: Giulia M Giordano; Francesco Brando; Pasquale Pezzella; Maria De Angelis; Armida Mucci; Silvana Galderisi Journal: Front Psychiatry Date: 2022-08-30 Impact factor: 5.435